MétaCan
Menu
Back to cohort

The introduction of bevacizumab for the treatment of metastatic colorectal cancer (CRC) in Ontario and its effect on hepatic metastectomy.

2012· article· en· W2560827114 on OpenAlexaffabout
W. Robert Leeper, Hector Hugo Li Chang, Stephen Welch, David K. Driman, Douglas Quan

Bibliographic record

VenueJournal of Clinical Oncology · 2012
Typearticle
Languageen
FieldMedicine
TopicColorectal Cancer Treatments and Studies
Canadian institutionsLondon Health Sciences Centre
Fundersnot available
KeywordsMedicineBevacizumabIrinotecanFOLFIRIColorectal cancerOxaliplatinInternal medicinePerioperativeFOLFOXOncologyRegimenChemotherapySurgeryCancer

Abstract

fetched live from OpenAlex

303 Background: Where possible, the optimal treatment for CRC liver metastases is metastectomy. Perioperative chemotherapy may be associated with improved outcomes in this setting. The government of Ontario approved public funding of bevacizumab (Bev) for metastatic CRC in July 2008. For first-line treatment, funding of Bev has been limited to use in combination with FOLFIRI, an irinotecan-containing regimen. However, the best evidence in support of perioperative chemotherapy for CRC liver metastases involves the use of oxaliplatin, not irinotecan. We sought to analyze changes in prescribing patterns, histologic findings, and clinical outcomes since the funding approval for Bev in Ontario. Methods: A single centre, retrospective review was performed of all patients receiving metastectomy for CRLM between 2004 and 2010, and archival hematoxylin-eosin slides were reviewed. Results: A total of 121 patients underwent metastectomy for CRLM during the study period. Of these, 54 were treated with perioperative chemotherapy, 37 before and 16 after funding approval of Bev. A marked increase was seen in Bev and irinotecan-containing regimens since funding approval (p < 0.01). Pathologic examination of the surgical specimens did not reveal any increase in steatosis or steatohepatitis. However, there was a trend towards more R0 resections (p = 0.3) in the post-bev era. A significant reduction in the occurrence of post-operative hepatic dysfunction was observed in the post-Bev era (p = 0.04). Overall survival (OS) and disease-free survival (DFS) were similar. Conclusions: Public funding of Bev-FOLFIRI for metastatic CRC has led to an increased and yet incomplete utilization of this regimen for CRLM. Pathologic and clinical data do not suggest harm and may show early signs of benefit. Further research is needed to determine the optimal utilization of bev in the setting of CRLM. [Table: see text]

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.746
Threshold uncertainty score0.512

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.111
GPT teacher head0.457
Teacher spread0.346 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicColorectal Cancer Treatments and StudiesFrench-language works237,207